(redirected from Gadolinium-Based Contrast Agent)
GBCAGreen Building Council of Australia
GBCAGadolinium-Based Contrast Agent
GBCAGeneral Building Contractors Association
GBCAGreater Baltimore Cultural Alliance (Maryland)
GBCAGalveston Bay Cruising Association
GBCAGreater Boston Concierge Association
GBCAGrassland Bird Conservation Area
GBCAGrizzly Bear Conservation Area
GBCAGraphics-Based Control Architecture
GBCAGreater Boston Cable Advertising
GBCAGranite Bay Community Association (Granite Bay, CA)
GBCAGerman Brown Coal Association
GBCAGreat Band of Christmas Aid
References in periodicals archive ?
The medical histories of 75 of these patients have been reviewed in detail, and all had received a gadolinium-based contrast agent.
The new guidelines give special attention to gadolinium-based contrast agents used during MR imaging in light of a rare but potentially fatal condition in patients with advanced kidney disease.
Until this study, there were limited data regarding the use of gadolinium-based contrast agents in pediatric patients younger than 2 years of age, and there has been a significant need to better understand how they work in our youngest patients, said Dr.
which manufactures the gadolinium-based contrast agent Magnevist, said that as of Dec.
15 March 2011 - Bayer HealthCare Pharmaceuticals Inc said Monday that the US Food and Drug Administration (FDA) has approved Gadavist (gadobutrol) Injection, a macrocyclic gadolinium-based contrast agent (GBCA), for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system (CNS).
The Food and Drug Administration issued a public health advisory stating that the agency has received reports of 90 patients with moderate- to end-stage kidney disease who developed the new disease within 2 days to 18 months after they had magnetic resonance imaging (MRI) or magnetic resonance angiography (MRA) with a gadolinium-based contrast agent.
These are performed as multiple breath-hold sequences before and at timed intervals after IV bolus injection of a gadolinium-based contrast agent.
Patients with reduced renal function are at risk of developing contrast-induced nephrotoxicity (CIN) following a contrast-enhanced computed tomography (CT) examination with an iodinated contrast agent (1) and at risk of developing nephrogenic systemic fibrosis (NSF) after a contrast-enhanced magnetic resonance imaging (MRI) examination with an extracellular gadolinium-based contrast agent.
58) Eleven of the 64 patients had a significant increase in serum creatinine after intravenous or intra-arterial administration of iodine-based contrast media, whereas none had increased serum creatinine levels after intravenous administration of a gadolinium-based contrast agent.